Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Eight Patent Applications Related to RNAi: Nov 30, 2006

Premium
Title: Sugar-Modified Oligonucleotides
 
Number: 7,138,517
 
Filed: Nov. 28, 2001
 
Lead Inventor: Phillip Dan Cook, Isis Pharmaceuticals
 
The patent, its abstract states, covers “compositions and methods … for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2'-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided,” the abstract adds.
 

 
Title: Methods for Producing Transgenic Animals with Modified Disease Resistance
 
Number: 20060265773
 
Filed: June 5, 2006
 
Lead Inventor: Miles Carroll, Oxford Biomedica
 
The patent application, its abstract states, comprises “a method or producing a transgenic animal having modified resistance to a disease. One embodiment of the method is performed by introducing a retrovirus into a cell of the animal or a cell which is capable of producing the animal, wherein the retrovirus comprises a polynucleotide sequence which encodes and is capable of expressing a protein [that] modifies the disease resistance of the animal.”
 

 
Title: Monitoring microRNA Expression and Function
 
Number: 20060265771
 
Filed: April 26, 2006
 
Lead Inventor: David Lewis, Mirus
 
In vivo endogenous microRNA activity can be observed over time using miRNA sensor plasmids capable of long term expression,” the patent application’s abstract states. “Using reporter genes whose expression can be monitored without sacrificing the animal enables the investigator to follow changes in miRNA expression though developmental stages or in response to environmental factors or treatment regimens.”
 

 
Title: Oncogene HOXB13 and its siRNAs
 
Number: 20060265765
 
Filed: May 19, 2005
 
Lead Inventor: Toshinori Agatsuma, Sankyo
 
The patent application, its abstract states, covers “a method of producing cancer cells using an oncogene, a method of detecting cancer using the cancer cell, a method of screening compounds having cancer therapeutic, and/or preventive effects and a cancer therapeutic and/or preventive pharmaceutical composition. There could be provided a method of detecting cancer using the expression of HOXB13 as an indicator wherein HOXB13 gene is excessively expressed in a cell, and a cell line in which cell growth ability is changed is selected; a method of screening compounds having novel cancer therapeutic, and/or preventive effects by using OXB13; a pharmaceutical composition; and a method of treating cancer using said pharmaceutical composition.”
 

 
Title: Composition for Treatment of Prevention of Endometrial Cancer and Method of Preventing or Treating Endometrial Cancer Using the Composition
 
Number: 20060264396
 
Filed: Aug. 22, 2005
 
Lead Inventor: Churl Ki Min, Ajou University
 
According to the patent application’s abstract, the invention comprises “a composition for the treatment or prevention of an endometrial cancer including a nuclear acid molecule inducing RNA interference against human syndecan-1 gene expression and a pharmaceutically acceptable carrier, and a method of treating or preventing an endometrial cancer including administering the composition to an individual.”
 

 
Title: Liver-Specific siRNAs for the Treatment of Therapy-Resistant Tumors
 
Number: 20060264394
 
Filed: April 15, 2004 PCT Filed: April 15, 2004
 
Lead Inventor: Karin Butz, Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
 
The patent application, its abstract states, covers “the use of siRNAs which are specific for the inhibitor of apoptosis protein livin to sensitize tumor cells for apoptosis by down-regulating livin expression.”
 

 
Title: System and Method for Identification of microRNA Precursor Sequences and Corresponding Mature microRNA Sequences from Genomic Sequences
 
Number: 20060263798
 
Filed: Feb. 10, 2006
 
Lead Inventor: Tien Huynh, International Business Machines
 
The patent application, its abstract states, covers “a method for determining microRNA precursors and their corresponding mature microRNAs from genomic sequences. For example, in one aspect of the invention, a method for determining whether a nucleotide sequence contains a microRNA precursor comprises the following steps: Patterns are generated by processing a collection of already known microRNA precursor sequences; one or more attributes are assigned to the generated patterns; only the patterns whose attributes satisfy certain criteria are subselected, and then the subselected patterns are used to analyze the nucleotide sequence,” the abstract states. “In another aspect of the invention, a method for identifying a mature microRNA sequence in a microRNA precursor sequence comprises the following steps: One or more patterns are generated by processing a collection of known mature microRNA sequences; the one or more patterns are filtered, and then used to locate instances of the one or more filtered patterns in one or more candidate precursor sequences.”
 

 
Title: Methods and Constructs for Evaluation of RNAi Targets and Effector Molecules
 
Number: 20060263764
 
Filed: Feb. 24, 2004 PCT Filed: Feb. 24, 2004
 
Inventor: Catherine Pachuk, Nucleonics
 
According to the patent application’s abstract, the invention comprises “methods and constructs for selecting double-stranded RNA molecules capable of post-transcriptional gene silencing or RNA interference, and methods of selecting targets susceptible to double-stranded RNA mediated PTGS or RNAi.”
 

 
Title: Inhibitors of Ribonucleotide Reductase Subunit 2 and Uses Thereof
 
Number: 20060263435
 
Filed: March 31, 2006
 
Lead Inventor: Mark Davis, Calando Pharmaceuticals
 
“The present application relates to inhibitors of ribonucleotide reductase subunit 2, and methods and compositions related to the R2 inhibitors,” the patent application’s abstract states. “In certain embodiments, the R2 inhibitors include nucleic acids, such as for example siRNAs.”
 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.